SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today unveiled its aspirational “5x5” Goal and announced its strategic priorities for 2016.
“2015 was yet another transformational year for Ignyta. With the successful acquisition or licensing of six new assets, three of which were either in the clinic or entered the clinic in 2015, Ignyta’s development stage pipeline quadrupled – undergoing an impressive transformation in less than one year,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “Based on our successes in 2015, we believe that Ignyta is uniquely positioned among companies of our size to develop meaningful treatment options for the benefit of cancer patients. We are relentlessly driven by this patient focus, which underlies our previously announced overarching, ‘audacious’ goal of eradicating residual disease in precisely defined cancer patient populations by 2030.”
“2015 was yet another transformational year for Ignyta. With the successful acquisition or licensing of six new assets, three of which were either in the clinic or entered the clinic in 2015, Ignyta’s development stage pipeline quadrupled – undergoing an impressive transformation in less than one year,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “Based on our successes in 2015, we believe that Ignyta is uniquely positioned among companies of our size to develop meaningful treatment options for the benefit of cancer patients. We are relentlessly driven by this patient focus, which underlies our previously announced overarching, ‘audacious’ goal of eradicating residual disease in precisely defined cancer patient populations by 2030.”
